Bone formation induced in an infant by systemic prostaglandin-E2 administration.
We report a case of long-term systemic administration of prostaglandin E2 (PGE2) to a newborn infant with ductus-dependent congenital heart disease. After 46 days of treatment, radiography showed cortical hyperostosis of the long bones. The child died 62 days after discontinuation of prostaglandin treatment. Histologic examination of tubular bones showed hyperostosis presumably due to prostaglandin-induced rapid formation of primitive bone. The additional finding of extensive resorption of the outer cortical surface and bone formation at the inner surface suggested a reversible phase after discontinuation of treatment.
Jørgensen
H R
HR
Department of Orthopedics, Odense University Hospital, Denmark.
Svanholm
H
H
Høst
A
A
D001846:Bone Development / Q000187:drug effects*; D001847:Bone Diseases / Q000139:chemically induced*; D015232:Dinoprostone; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy; D005260:Female; D006330:Heart Defects, Congenital / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D011458:Prostaglandins E / Q000009:adverse effects* / Q000627:therapeutic use
D011458:Prostaglandins E; D015232:Dinoprostone